Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach-Reference-Cited by-同舟云学术

Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach

Published:2018-08-20 Issue:12 Volume:34 Page:2063-2073
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Antonini Angelo¹,Stoessl A. Jon²,Kleinman Leah S.³,Skalicky Anne M.³,Marshall Thomas S.⁴,Sail Kavita R.⁴,Onuk Koray⁴,Odin Per Lars Anders⁵⁶

Affiliation:

1. Department of Neuroscience, University of Padua, Padova, Italy;

2. Pacific Parkinson’s Research Centre, Vancouver, BC, Canada;

3. Evidera, Bethesda, MD, USA;

4. AbbVie, North Chicago, IL, USA;

5. Department of Neurology, Lund University, Skåne University Hospital, Lund Sweden;

6. Klinikum-Bremerhaven, Bremerhaven, Germany

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1502165

Reference53 articles.

1. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation

2. Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonʼs Disease

3. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): [RETIRED]

4. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program

5. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations;Parkinsonism & Related Disorders;2024-10

2. Are 5-2-1 Delphi criteria and MANAGE-PD useful screening tools for general neurologists for qualification to device-aided therapies in advanced Parkinson’s Disease?;Neurologia i Neurochirurgia Polska;2024-08-28

3. Prevalence of Thai patients with advanced Parkinson’s disease and external validation of the 5–2-1 Criteria and the CDEPA Questionnaire: A single-centered, cross-sectional study;Clinical Neurology and Neurosurgery;2024-08

4. Influence of continuous subcutaneous apomorphine infusion on cognition and behavior in Parkinson's disease: A systematic review;Revue Neurologique;2024-08

5. Response to letter to the editor regarding “Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries”;BMC Neurology;2024-07-30